A simple blood draw to evaluate cfDNA might one day be used for early-stage lung cancer screening—if the mutational “noise” of normal aging can be addressed.
Genetic sequencing of tumors to identify targeted therapy options appears to delay tumor progression and prolong patient survival.
The PI3K inhibitor taselisib offered less dramatic clinical benefits than anticipated, and with significant toxicities.
Combining the ALK inhibitor with this immunotherapeutic agent had an acceptable safety profile and yielded an ORR of 85.7%, South Korean investigators reported.
No one molecular biomarker is likely to guide treatment of RCC in the foreseeable future. Multipredictor models might be a way forward, an expert concluded.
Activating oncogene mutations do not predict lung tumor responses to immune checkpoint blockade, ImmunoTarget investigators found.
Can you name biomarkers that are associated with PCNS-DLBCL? Are you aware of contraindications for use of rituximab in DLBCL? Test your knowledge by taking this multiquestion quiz.
Challenge yourself with our latest quiz, covering management considerations in the treatment of patients with transplant-ineligible myeloma.
What are appropriate sources of stem cells for HCT in patients without an HLA-matched, related donor? Is post-transplant cyclophosphamide–based haploidentical donor transplantation appropriate for racial and ethnic minority patients with hematologic cancers? Test your knowledge with this multiquestion quiz.
Pooled data show PET imaging of metabolic tumor burden at diagnosis helps identify patients most at risk of FL recurrence.